权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Autoantibodies Define Scleroderma Subgroups with Distinct Relationships to Cancer

自身抗体定义了与癌症具有独特关系的硬皮病亚群

基本信息

批准号：
10378073
负责人：
LIVIA A CASCIOLA-ROSEN
金额：
$ 61.31万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-04-09 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10378073
关键词：
Antibodies Antibody Specificity Antigen Targeting Antigens Autoantibodies Autoantigens Autoimmune Responses Autoimmunity Biological Biological Assay Cancer Detection Centromere Chronic Clinical Cohort Analysis Complex Computer Analysis Control Groups Custom Data Development Differentiation Antigens Disease Drug Exposure Epitopes General Population Genes Genetic High-Risk Cancer Histology Immune response Immunologic Factors Immunoprecipitation Incidence Inflammation Kinetics Link Malignant Neoplasms Matched Group Methods Mutate Mutation Myositis Onset of illness Pathogenesis Patients Pattern Phenotype Population Proteomics RNA Polymerase III Registries Rheumatism SEER Program Scleroderma Screening for cancer Serology Site Somatic Mutation Specificity Standardization Stratification Subgroup Testing Therapeutic Time Tissues Topoisomerase Universities Validation Work anti-cancer autoimmune rheumatologic disease cancer risk cancer type clinically relevant cohort evidence base high risk population innovation insight novel novel marker patient subsets population based response screening screening guidelines tool tumor validation studies

项目摘要

PROJECT SUMMARY Although an understanding of the biological mechanisms causing scleroderma (SSc) remains incomplete, emerging data underscore important connections linking cancer, autoimmunity and SSc. It is an important priority to identify SSc subgroups at high risk of cancer at SSc onset, as this may inform therapeutic approaches and provide insights into SSc pathogenesis. Our recent studies show that autoantibodies are useful to define biologically relevant subgroups. Among SSc patients with cancer, those with anti-RNA polymerase III (POLR3) antibodies are more likely to have cancer close to SSc onset (3, 4). However, >25% of patients with a short cancer-SSc interval currently have undefined autoantibodies. We have created an innovative autoantibody discovery pipeline, and demonstrate that multiple, additional autoantibodies (known and novel) are associated with coincident cancer at SSc onset. We also describe a novel antibody specificity that is enriched in anti-POLR3-positive patients who do not get cancer, suggesting that some immune responses might be protective against cancer. Lastly, we demonstrate that autoantibody subsets can aid in defining the magnitude and timing of cancer risk in SSc, and in predicting the types of tumors observed. The proposed studies will use a large population of SSc patients from two well-characterized SSc cohorts to define and validate autoantibodies associated with increased or decreased cancer risk, and to assess their utility, together with distinct phenotypic features, in quantifying cancer risk at SSc onset. We will accomplish this through the following specific aims: Aim 1 will use an innovative antibody discovery pipeline and a rich cohort of SSc patients with cancer to identify known and novel autoantibody markers of a short cancer-SSc interval in patients lacking the 3 major SSc antibody specificities. The studies will also use the defined autoantibodies to search for evidence of somatic mutations of relevant autoantigens in matched cancers. Since ~80% of patients with POLR3 antibodies do not have cancer, and our preliminary data shows novel antibodies in this group, we will also identify autoantibodies associated with protection against cancer. These may be important markers of low cancer risk. Aim 2 will define time-dependent overall and site-specific cancer risk in patients with SSc relative to the general population, based on autoantibody and phenotypic subsets, to develop an evidence-based approach to cancer screening in patients with new onset SSc. Findings will be validated in a second large SSc cohort. This work will allow the development of a clinically relevant approach to cancer detection at SSc onset and establish a framework of more homogeneous serologic subgroups in whom the mechanistic relationships between cancer and autoimmunity can be interrogated. This approach is also relevant to other autoimmune rheumatic diseases (e.g. inflammatory myopathies) in which cancer and rheumatic disease onset are temporally linked.

项目总结